These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25929861)

  • 1. Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance.
    Wang X; Li X; Fu X; Bai M; Li X; Mei Q; Nie J; Wu Z; Han W
    Curr Protein Pept Sci; 2015; 16(4):270-8. PubMed ID: 25929861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets.
    Ahmed N; Abubaker K; Findlay JK
    Mol Aspects Med; 2014 Oct; 39():110-25. PubMed ID: 23811037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S100B promotes chemoresistance in ovarian cancer stem cells by regulating p53.
    Yang T; Cheng J; You J; Yan B; Liu H; Li F
    Oncol Rep; 2018 Sep; 40(3):1574-1582. PubMed ID: 29956807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism.
    Li SS; Ma J; Wong AST
    J Gynecol Oncol; 2018 Mar; 29(2):e32. PubMed ID: 29468856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in ovarian tumor stem cells and therapy.
    Chen B; Liu J
    Cell Biochem Biophys; 2024 Sep; 82(3):1871-1892. PubMed ID: 38955927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cancer stem cell: A potential therapeutic target for overcoming multidrug resistance.
    Mihanfar A; Aghazadeh Attari J; Mohebbi I; Majidinia M; Kaviani M; Yousefi M; Yousefi B
    J Cell Physiol; 2019 Apr; 234(4):3238-3253. PubMed ID: 30317560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.
    Deng J; Wang L; Chen H; Hao J; Ni J; Chang L; Duan W; Graham P; Li Y
    Oncotarget; 2016 Aug; 7(34):55771-55788. PubMed ID: 27304054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rad6 upregulation promotes stem cell-like characteristics and platinum resistance in ovarian cancer.
    Somasagara RR; Tripathi K; Spencer SM; Clark DW; Barnett R; Bachaboina L; Scalici J; Rocconi RP; Piazza GA; Palle K
    Biochem Biophys Res Commun; 2016 Jan; 469(3):449-55. PubMed ID: 26679603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term treatment of metformin impedes development of chemoresistance by regulating cancer stem cell differentiation through taurine generation in ovarian cancer cells.
    Bishnu A; Sakpal A; Ghosh N; Choudhury P; Chaudhury K; Ray P
    Int J Biochem Cell Biol; 2019 Feb; 107():116-127. PubMed ID: 30593952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
    Glackin CA
    Enzymes; 2018; 44():83-101. PubMed ID: 30360816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer.
    Ahmed N; Abubaker K; Findlay J; Quinn M
    Curr Cancer Drug Targets; 2010 May; 10(3):268-78. PubMed ID: 20370691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
    Ahmed N; Abubaker K; Findlay J; Quinn M
    J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of cancer stem cells in progressive growth and resistance of ovarian cancer: true or fiction?].
    Bar JK; Grelewski P; Lis-Nawara A; Drobnikowska K
    Postepy Hig Med Dosw (Online); 2015 Sep; 69():1077-86. PubMed ID: 26400893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD10
    Ffrench B; Gasch C; Hokamp K; Spillane C; Blackshields G; Mahgoub TM; Bates M; Kehoe L; Mooney A; Doyle R; Doyle B; O'Donnell D; Gleeson N; Hennessy BT; Stordal B; O'Riain C; Lambkin H; O'Toole S; O'Leary JJ; Gallagher MF
    Cell Death Dis; 2017 Oct; 8(10):e3128. PubMed ID: 29048400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insight into NANOG: A novel therapeutic target for ovarian cancer (OC).
    Mahalaxmi I; Devi SM; Kaavya J; Arul N; Balachandar V; Santhy KS
    Eur J Pharmacol; 2019 Jun; 852():51-57. PubMed ID: 30831081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling.
    Qian J; LeSavage BL; Hubka KM; Ma C; Natarajan S; Eggold JT; Xiao Y; Fuh KC; Krishnan V; Enejder A; Heilshorn SC; Dorigo O; Rankin EB
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
    Zanotti L; Romani C; Tassone L; Todeschini P; Tassi RA; Bandiera E; Damia G; Ricci F; Ardighieri L; Calza S; Marchini S; Beltrame L; Tognon G; D'Incalci M; Pecorelli S; Sartori E; Odicino F; Ravaggi A; Bignotti E
    BMC Cancer; 2017 May; 17(1):366. PubMed ID: 28545541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer.
    Chien JR; Aletti G; Bell DA; Keeney GL; Shridhar V; Hartmann LC
    J Cell Biochem; 2007 Dec; 102(5):1117-29. PubMed ID: 17879946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
    Raghavan S; Mehta P; Ward MR; Bregenzer ME; Fleck EMA; Tan L; McLean K; Buckanovich RJ; Mehta G
    Clin Cancer Res; 2017 Nov; 23(22):6934-6945. PubMed ID: 28814433
    [No Abstract]   [Full Text] [Related]  

  • 20. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
    Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
    Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.